The report covers emerging Idiopathic Membranous Nephropathy drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Idiopathic Membranous Nephropathy treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Idiopathic Membranous Nephropathy: An Overview
Idiopathic Membranous Nephropathy (IMN) is a kidney disorder characterized by inflammation and damage to the glomeruli, which are tiny filtering units within the kidneys. IMN is the most common cause of nephrotic syndrome in adults. It is more prevalent in middle-aged and older individuals, with a slight male predominance.
IMN is considered an autoimmune disorder because it involves the immune system attacking the body’s own tissues. In this condition, antibodies called anti-phospholipase A2 receptor antibodies (PLA2R antibodies) are often detected in the blood of affected individuals. IMN typically presents with symptoms of nephrotic syndrome, including significant proteinuria (excess protein in the urine), edema (swelling), hypoalbuminemia (low levels of albumin in the blood), and hyperlipidemia (elevated blood lipid levels).
IMN can have a variable course, with some individuals experiencing spontaneous remission, while others may progress to chronic kidney disease (CKD) over time. Around 30-40% of patients with IMN progress to end-stage renal disease (ESRD) within 10 years if left untreated. The diagnosis of IMN involves a combination of clinical features, laboratory tests (such as urine analysis, serum creatinine, and serum albumin), imaging studies, and kidney biopsy. The biopsy is crucial to confirm the presence of immune deposits in the glomeruli.
The management of IMN aims to reduce proteinuria, prevent disease progression, and manage complications. Initial treatment often includes supportive measures like controlling blood pressure and cholesterol levels. Immunosuppressive therapies, such as corticosteroids, alkylating agents (e.g., cyclophosphamide), and calcineurin inhibitors (e.g., cyclosporine), may be considered for patients at high risk of progression. Recent advances in understanding the pathogenesis of IMN have led to the development of targeted therapies. Novel treatments, including B cell-targeted therapies (rituximab) and anti-CD20 monoclonal antibodies, have shown promise in clinical trials.
Idiopathic Membranous Nephropathy Market Key Facts
-
In 2022, the US captured the highest market share (60%) of all the 7MM countries.
-
Among EU4 countries, Germany accounts for the maximum market size in 2022, while France occupies the bottom of the ladder in 2022.
-
In Japan, the Idiopathic Membranous Nephropathy market size is expected to increase at a CAGR of ~4% during the study period (2019–2032).
-
The total Idiopathic Membranous Nephropathy cases in the US were approximately 29,000 in 2022 and are projected to increase during the forecast period (2023–2032).
-
In 2022, the US accounted for approximately 19,000 cases in the addressable pool of Idiopathic Membranous Nephropathy.
-
Among the EU4 countries, Germany accounted for the largest number of Idiopathic Membranous Nephropathy cases, followed by the UK, whereas France accounted for the lowest number of cases in 2022.
-
In 2022, total Idiopathic Membranous Nephropathy cases in Japan were approximately 16,000, estimated to increase during the forecast period (2023–2032).
Idiopathic Membranous Nephropathy Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Idiopathic Membranous Nephropathy pipeline therapies. It also thoroughly assesses the Idiopathic Membranous Nephropathy market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Idiopathic Membranous Nephropathy drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Idiopathic Membranous Nephropathy Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Idiopathic Membranous Nephropathy epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Idiopathic Membranous Nephropathy epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
Idiopathic Membranous Nephropathy Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Idiopathic Membranous Nephropathy market or expected to be launched during the study period. The analysis covers the Idiopathic Membranous Nephropathy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Idiopathic Membranous Nephropathy drugs based on their sale and market share.
The report also covers the Idiopathic Membranous Nephropathy pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Idiopathic Membranous Nephropathy companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Idiopathic Membranous Nephropathy Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/idiopathic-membranous-nephropathy-imn-market
Idiopathic Membranous Nephropathy Companies Actively Working in the Therapeutics Market Include
-
Hoffmann-La Roche
-
MorphoSys
-
Cerium Pharmaceuticals
-
BeiGene
-
Reistone Biopharma
-
Eternity Bioscience
-
GlaxoSmithKline
-
ValenzaBio
-
ACELYRIN
And Many Others
Emerging and Marketed Idiopathic Membranous Nephropathy Therapies Covered in the Report Include:
-
GAZYVA (Hoffmann-La Roche)
-
MOR202 (MorphoSys)
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/idiopathic-membranous-nephropathy-imn-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Idiopathic Membranous Nephropathy Competitive Intelligence Analysis
4. Idiopathic Membranous Nephropathy Market Overview at a Glance
5. Idiopathic Membranous Nephropathy Disease Background and Overview
6. Idiopathic Membranous Nephropathy Patient Journey
7. Idiopathic Membranous Nephropathy Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Idiopathic Membranous Nephropathy Treatment Algorithm, Current Treatment, and Medical Practices
9. Idiopathic Membranous Nephropathy Unmet Needs
10. Key Endpoints of Idiopathic Membranous Nephropathy Treatment
11. Idiopathic Membranous Nephropathy Marketed Therapies
12. Idiopathic Membranous Nephropathy Emerging Drugs and Latest Therapeutic Advances
13. Idiopathic Membranous Nephropathy Seven Major Market Analysis
14. Attribute Analysis
15. Idiopathic Membranous Nephropathy Market Outlook (In US, EU5, and Japan)
16. Idiopathic Membranous Nephropathy Companies Active in the Market
17. Idiopathic Membranous Nephropathy Access and Reimbursement Overview
18. KOL Views on the Idiopathic Membranous Nephropathy Market
19. Idiopathic Membranous Nephropathy Market Drivers
20. Idiopathic Membranous Nephropathy Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/idiopathic-membranous-nephropathy-imn-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Paraganglioma Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Paraganglioma market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Paraganglioma market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/